Duloxetine + placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Depressive Disorder, Major

Conditions

Depressive Disorder, Major

Trial Timeline

Mar 1, 2005 → Jan 1, 2008

NCT ID

NCT00105989

About Duloxetine + placebo

Duloxetine + placebo is a phase 3 stage product being developed by Eli Lilly for Depressive Disorder, Major. The current trial status is completed. This product is registered under clinical trial identifier NCT00105989. Target conditions include Depressive Disorder, Major.

What happened to similar drugs?

20 of 20 similar drugs in Depressive Disorder, Major were approved

Approved (20) Terminated (0) Active (0)

✅Mirtazapine TabletsSun PharmaceuticalApproved

✅DuloxetineEli LillyApproved

✅duloxetine hydrochlorideEli LillyApproved

✅DuloxetineEli LillyApproved

✅Duloxetine hydrochlorideEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01931475	Phase 3	Completed	Sep 1, 2013	Jun 1, 2015	Osteoarthritis
NCT01451606	Approved	Terminated	Jul 11, 2011	Nov 4, 2015	Pelvis Pain Chronic
NCT01226511	Phase 3	Completed	Jun 1, 2011	Jun 1, 2013	Anxiety Neuroses
NCT01179672	Phase 3	Completed	Apr 1, 2011	Aug 1, 2013	Diabetic Neuropathy, Painful
NCT01237587	Phase 3	Completed	Mar 1, 2011	Nov 28, 2017	Fibromyalgia
NCT01118780	Approved	Completed	Oct 1, 2010	Jul 1, 2012	Generalized Anxiety Disorder
NCT01070329	Approved	Completed	Mar 1, 2010	Mar 1, 2011	Major Depressive Disorder
NCT01000805	Approved	Completed	Nov 1, 2009	Oct 1, 2010	Major Depressive Disorder
NCT01018680	Phase 3	Completed	Nov 1, 2009	Apr 1, 2011	Osteoarthritis Knee Pain
NCT00965081	Approved	Completed	Sep 1, 2009	Nov 1, 2010	Fibromyalgia, Primary
NCT00803361	Phase 3	Completed	Dec 1, 2008	Jan 1, 2010	Generalized Anxiety Disorder
NCT00767806	Phase 3	Completed	Sep 1, 2008	Jul 1, 2009	Chronic Low Back Pain
NCT00433290	Phase 3	Completed	Feb 1, 2007	May 1, 2008	Osteoarthritis Knee Pain
NCT00424593	Phase 3	Completed	Jan 1, 2007	Oct 1, 2008	Back Pain Without Radiation
NCT00457730	Phase 2/3	Completed	Jan 1, 2007	Aug 1, 2012	Multiple Sclerosis
NCT00408876	Phase 3	Completed	Dec 1, 2006	Nov 1, 2007	Back Pain Without Radiation
NCT00408421	Phase 3	Completed	Nov 1, 2006	Oct 1, 2007	Osteoarthritis Knee Pain
NCT00607789	Approved	Completed	Oct 1, 2006	Oct 1, 2009	Binge Eating
NCT00375973	Phase 2/3	Completed	Sep 1, 2006	Mar 1, 2014	Fatigue Syndrome, Chronic
NCT00233025	Phase 3	Completed	Sep 1, 2005	Jun 1, 2007	Fibromyalgia

Competing Products

20 competing products in Depressive Disorder, Major

See all competitors

Product	Company	Stage	Hype Score
duloxetine	Eli Lilly	Pre-clinical	26
Duloxetine Hydrochloride	Eli Lilly	Pre-clinical	26
LY2216684	Eli Lilly	Phase 1	29
LY2216684	Eli Lilly	Phase 1	29
Duloxetine	Eli Lilly	Phase 3	40
LY2216684 + Digoxin	Eli Lilly	Phase 1	29
Duloxetine + Paroxetine	Eli Lilly	Phase 3	40
LY2216684 + Placebo + Escitalopram	Eli Lilly	Phase 2	35
FK949E	Astellas Pharma	Phase 1	29
quetiapine extended release (XR) + Placebo	Astellas Pharma	Phase 2	35
FK949E	Astellas Pharma	Phase 1	29
FK949E	Astellas Pharma	Phase 1	29
FK949E	Astellas Pharma	Phase 1	29
Mirtazapine Tablets	Sun Pharmaceutical	Approved	43
Duloxetine Hydrochloride	Shionogi	Phase 3	32
Duloxetine Hydrochloride + Placebo	Shionogi	Phase 3	40
ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1	Ono Pharmaceutical	Phase 2	35
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	39
Pramipexole ER + Escitalopram	Cipla	Phase 2	42
LY2216684 + Sertraline	Eli Lilly	Phase 1	29